Antares Pharma (NASDAQ: ATRS) reported Q2 EPS of ($0.03), $0.01 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $4.5 million versus the consensus estimate of $4.62 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

Earnings